EP Patent

EP2413933B2 — 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide for the treatment of migraine via the oral or intravenous route

Assigned to Colucid Pharmaceuticals Inc · Expires 2021-06-09 · 5y expired

What this patent protects

Patent listed against lasmiditan-succinate.

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: EP2413933B2
Jurisdiction: EP
Classification: —
Expires: 2021-06-09
Drug substance claim: No
Drug product claim: No
Assignee: Colucid Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.